Document is current
Any future updates will be listed below
-
Authors
Kwong, Anna Ka-Yee
Tsang, Mandy Ho-Yin
Fung, Jasmine Lee-Fong
Mak, Christopher Chun-Yu
Chan, Kate Lok-San
Rodenburg, Richard J. T.
Lek, Monkol
Huang, Shushu
Pajusalu, Sander
Yau, Man-Mut
Tsoi, Cheung
Fung, Sharon
Liu, Kam-Tim
Ma, Che-Kwan
Wong, Sheila
Yau, Eric Kin-Cheong
Tai, Shuk-Mui
Fung, Eva Lai-Wah
Wu, Nick Shun-Ping
Tsung, Li-Yan
Smeitink, Jan
Chung, Brian Hon-Yin https://orcid.org/0000-0002-7044-5916
Fung, Cheuk-Wing
-
Funding
Funding for this research was provided by:
the Society for the Relief of Disabled Children
the Joshua Hellmann Foundation for Orphan Disease
the Edward and Yolanda Wong Fund
- License Information
-
More Information
Article History
Received: 27 October 2020
Accepted: 6 January 2021
First Online: 15 January 2021
Ethics approval and consent to participate
: This study has been approved by the Institutional Review Board of the Hong Kong West Cluster and the University of Hong Kong (IRB Ref. Nos.: UW 11-190 and UW 12-221). Written informed consent was obtained from the patients and/or parents.
: Consent was obtained from all patients for publication.
: Anna Ka-Yee KWONG, Mandy Ho-Yin TSANG, Jasmine Lee-Fung FUNG, Christopher Chun-Yu Mak, Kate Lok-San Chan, Richard J.T. RODENBURG, Monkol LEK, Shushu HUANG, Sander PAJUSALU, Man-Mut YAU, Cheung TSOI, Sharon FUNG, Kam-Tim LIU, Che-Kwan MA, Sheila Wong, Eric Kin-Cheong YAU, Shuk-Mui TAI, Eva Lai-Wah FUNG, Nick Shun-Ping WU, Li-Yan TSUNG, Brian Hon-Yin CHUNG, Cheuk-Wing FUNG report no conflict of interest. Jan SMEITINK is the CEO of Khondrion, a pharmaceutical company developing compounds to potentially treat mitochondrial disease.
